Autopsy report · NCT01796522

Utility of Tocolytic Therapy for Maintenance Tocolysis in the Management of Threatened Preterm Delivery

“have been published new studies that it showed the ineffectiveness of the treatments proposed in this study.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

Instituto de Investigacion Sanitaria La Fe

Sponsor type

University, hospital or other

Conditions

Preterm Delivery.

Interventions

progesterone 200 mg / day vaginally; nifedipine (60 mg / day orally)

Participants

0

Sites

1

Countries

Spain

Trials that died the same way

• In-Vivo Activated T-Cell Depletion to Prevent GVHD
  “Treatment ineffective” (70% match in meaning)
• A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)
  “This study was terminated due to limited efficacy and not due to safety reasons” (67% match in meaning)
• Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer
  “The study was terminated on the basis on an evaluation of the safety and efficacy of the 9 included patients of which 2 of the patients were excluded before receiving any study treatments, thus 7 patients were treated in the study.” (67% match in meaning)
• Electroporation and Immunotherapy in Metastatic Colorectal Cancer
  “The study was terminated on the basis on an evaluation of the efficacy and safety of the 4 included and treated patients.” (67% match in meaning)
• Influence of Atorvastatin on Viral Replication During Antiretroviral Treatment Interruption
  “On the basis of published results of SMART study, it has been observed that the results are worse in patients who have interrupted their treatments.” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.